NDA Submitted for Duchenne Muscular Dystrophy Drug

Share this content:
NDA Submitted for Duchenne Muscular Dystrophy Drug
NDA Submitted for Duchenne Muscular Dystrophy Drug

PTC Therapeutics announced the completion of their rolling submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).  

The FDA has previously granted Translarna Orphan Drug status for DMD, cystic fibrosis (CF), Mucopolysaccharidosis I (MPS I), and aniridia.

RELATED: Drisapersen Gets Lukewarm Review from FDA

Translarna is an investigational, first-in-class, oral protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation such as in nmDMD.

Reference

PTC Therapeutics press release

You must be a registered member of Neurology Advisor to post a comment.
close

Next Article in Neuromuscular Disorders

Sign Up for Free e-newsletters



CME Focus